CD8A and neoplasm: In addition, low-dose fruquintinib in combination with an anti-PD-1 antibody appeared to enhance the anti-tumor immune response, reduce angiogenesis, increase the infiltration of CD8+ T cells, decrease the proportion of immunosuppressive cells such as macrophages and myeloid-derived suppressor cells (MDSCs), and improve the tumor immune microenvironment [34].